key: cord-0844378-5lxj6i7k
authors: Mistry, Pramod; Balwani, Manisha; Barbouth, Deborah; Burrow, T. Andrew; Ginns, Edward I.; Goker-Alpan, Ozlem; Grabowski, Gregory A.; Kartha, Reena V.; Kishnani, Priya S.; Lau, Heather; Lee, Chung U.; Lopez, Grisel; Maegawa, Gustavo; Packman, Seymour; Prada, Carlos; Rosenbloom, Barry; Lal, Tamanna Roshan; Schiffmann, Rapheal; Weinreb, Neal; Sidransky, Ellen
title: Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
date: 2020-05-11
journal: Mol Genet Metab
DOI: 10.1016/j.ymgme.2020.05.002
sha: 1680266a3608790e09f55c54ae83018e88896057
doc_id: 844378
cord_uid: 5lxj6i7k

nan

I.

In the late winter of 2019, emergence of the SARS-COV-2 virus led to the COVID-19 pandemic, manifesting in a serious illness affecting over a million people around the world, including the United States, during the spring of 2020. [1] During this pandemic, people with preexisting medical conditions are at higher risk of severe, potentially life-threatening effects of SARS CoV2 infection. [2] Not only is there the likelihood of increased morbidity and mortality if these individuals become infected with the virus, but the social and economic consequences of COVID-19 may significantly impact their access to critical healthcare resources. Among individuals with rare diseases, the implications of the pandemic may be unique, and can present specific management challenges. Moreover, the pandemic provides an unprecedented opportunity to research aspects related to immunity, lysosomal dysfunction and disease pathogenesis in distinct rare disease communities which will ultimately enhance clinical care. A group of investigators and physician experts in Gaucher disease along with patient advocacy organizations in the United States convened to propose management guidelines and to identify research questions during these challenging times. The overarching goal of this collaborative group is to delineate the emerging impact of the SARS-CoV-2 pandemic on patients with Gaucher disease and to develop optimal clinical practice guidelines for managing the infection.

Gaucher disease (GD) is caused by recessively inherited homozygous or biallelic pathogenic variants in GBA1, the gene encoding the lysosomal enzyme, glucocerebrosidase (GCase, acid -glucosidase, EC 3.2.1.45). These variants lead to varying degrees of deficient and/or defective glucocerebrosidase function, and the lysosomal accumulation of excess glucosylceramide (glucocerebroside, Gb1), glucosylsphingosine (lyso-Gb1), and other sphingolipids. [3, 4] GD is among the most common lysosomal diseases affecting approximately 1 in 40,000 individuals. However, in the Ashkenazi Jewish population, the frequency is much higher, affecting as many as 1 in 850 individuals. The disease is characterized by vast phenotypic heterogeneity and is classically divided into nonneuronopathic (type 1, GD1) and neuronopathic types (GD2 and GD3). These variants share the common feature of major systemic macrophage involvement, manifesting with varying J o u r n a l P r e -p r o o f degrees of hepatosplenomegaly, cytopenia and bone disease. There is accumulation of glycosphingolipid-laden macrophages ("Gaucher cells") in the spleen, liver, lymphoid and hematopoietic tissues, and somewhat infrequently, in the lung or kidney [4, 5] . A subset of patients, especially those that have undergone prior splenectomy for hypersplenism, develop pulmonary vascular disease manifesting as pulmonary hypertension or hepatopulmonary syndrome. Additionally, in GD1 there are age-related phenotypes in a small subset of patients that can include gammopathy/myeloma, other hematological malignancies and certain solid organ malignancies. [6] The neuronopathic forms have a spectrum of brain involvement, ranging from a rapidly progressive lethal neurodegenerative disorder of infancy (GD2) to more indolent and variable CNS involvement with eye movement abnormalities (gaze palsy), a hallmark neurological manifestation (GD3). [7] A subset of patients with GD, as well as their heterozygous carrier relatives, have an increased life-time risk of developing Parkinson disease, although the complete mechanism underlying this association is not fully delineated. [8] The degree of clinical heterogeneity in GD is remarkable, and can be viewed as a continuum of phenotypes. [9] In general, prior to treatment patients with GD have impaired macrophage function and immune dysregulation involving multiple myeloid cell lineages leading to chronic metabolic inflammation. [10] [11] [12] [13] [14] Additionally, some patients had splenectomies performed before the advent of therapy, and others harbor immunological abnormalities. [15] Together, these factors could portend poor outcome when patients with GD encounter infectious disease.

Effective treatments for Gaucher disease are available that successfully reverse many of the systemic non-neurological manifestations of the disease. Administration of the two therapies, enzyme replacement therapy (ERT) [16] and therapy preventing substrate accumulation (SRT) (for GD1) [17] are widely used. Each has specific considerations that may be impacted by aspects of the COVID-19 pandemic.

Are patients with Gaucher disease at increased risk of COVID-19 infection relative to the general population?

In the general population, SARS-CoV-2 has a higher infectious risk and mortality compared to J o u r n a l P r e -p r o o f seasonal influenza. [18] Older adults and people of all ages who have serious underlying medical conditions are at higher risk for severe illness from COVID-19. [19] Specific risk factors for poor outcome from SARS-CoV-2 include male sex, diabetes mellitus types 1 and 2, obesity, preexisting heart disease, kidney disease, hypertension, immunodeficiency and chronic lung disease.

Three stages of SARS-CoV-2 disease are recognized, which is important to keep in mind when managing patients with GD infected with the virus. In stage 1, [20] inhalation of viral particles is followed by ACE2 receptor-mediated uptake and endolysosomal processing of the virus by target cells in the lungs [21] . Early symptoms include fatigue, cough and fevers. The majority of patients (~80%) recover from the infection at this stage, and treatment is only symptomatic.

Some 15% of patients progress to silent or overt pulmonary disease (without or with hypoxemia, respectively) and inflammation that appears to prominently involve the interaction of infected cells with macrophages and other myeloid cells (stage 2) [22] . On chest X-ray or CT scan, 

There are also some further considerations. Prior to the advent of current therapies, many patients were treated by splenectomy, and a significant proportion of the older US patients with GD are asplenic. [31] Baseline studies in patients with GD have demonstrated abnormal immunoglobulin levels, some with monoclonal gammopathy, and immune phenotyping has suggested other impairments. [32] [33] [34] Rare patients with pulmonary alveolar and interstitial infiltration or pulmonary hypertension may specifically be at risk. [35] Historically, the role of avoiding hospitals and clinics where they may be exposed to patients with COVID-19. In the current environment, patients are understandably anxious about allowing home infusions or going to infusions centers, lest they become exposed to a health care worker who is an asymptomatic carrier of SARS-CoV-2. Individual discussions with the treating physician regarding the status of the patient's GD, as well as the logistics of receiving ERT is essential. Some infusion centers and home infusion companies have rapidly adapted to these changed circumstances to continue uninterrupted ERT, but this continues to be a challenge. The availability of home infusion nurses may also be compromised due to nursing shortages, as well as prioritization of availability of personal protective equipment for hospitals overwhelmed with SARS-CoV-2 patients, depending on geographical locations.

Until we understand more about the rate of progression and mechanism of SARS-CoV-2 infection in patients with GD, the general recommendation is not to stop infusions.

However, under certain circumstances this may be unavoidable. It is imperative that the decision to alter or halt therapy be made with the input of a GD specialist. In patients who are extremely stable under chronic therapy, it is possible that drug interruptions of weeks to months could be tolerated, as happened during a several month drug shortage a decade ago. [60, 61] However, these previously studied treatment gaps did not occur in the context of a severe pandemic. A preferable option to discontinuation of ERT may be to extend the interval of drug infusions, as there is also some evidence that infusions of higher doses given at three-or four-week intervals are effective under certain circumstances. [62] Monitoring the disease before and after any adjustments to the normal administration regimen will be essential, and may help to inform future management. It is recommended that newly started symptomatic patients, unstable patients and those with type 3 GD make every effort to continue their therapy. Those with unavoidable interruptions in therapy should be followed at closer periodic intervals than usual to assess potential worsening of their GD status. • Is the frequency of infection among patients with GD different than that seen in the general population?

• Is there a correlation with age, sex, ethnicity, body mass index, blood type or therapy status?

• Does the GBA1 genotype or a specific GD phenotype impact the activity and progression of co-existing SARS-CoV-2 infection?

• What is the pattern and natural history of SARS-CoV-2 infection in GD patients?

What is the prevalence of asymptomatic and/or mildly symptomatic COVID-19

positive individuals among patients with mild and more severe manifestation of GD? Do different disease manifestation or comorbidities impact infection rate and/or natural history? Are there indicators of prognosis?

• Because SARS-CoV-2 takes advantage of the lysosomal/endosomal system to infect cells, would genetic variants of genes encoding lysosomal resident-proteins including GBA1 impact SARS-CoV-2 infection course and manifestations?

b) The impact of the pandemic on the patient community: Given the significant socioeconomic and psychological implications of the current pandemic, we propose to survey this patient population with an already existing chronic and rare disorder to assess how they perceive their disease has impacted their medical care during the pandemic, as well as their emotional and psychological health. This will help us to better understand what healthcare resource gaps this rare disease community have identified during the COVID-19 pandemic and how these challenges impact the delivery of optimal health care to these and similarly affected patients. It will also be important to evaluate whether any therapy changes or gaps that occurred during this pandemic impacted their disease.

c) The response of patients with Gaucher disease to COVID-19 and/or it's pharmacological interventions: The prospective collection of clinical samples together with clinical data J o u r n a l P r e -p r o o f will enable us to determine the response to the infection (symptomatic and asymptomatic)

in patients with GD. This will entail collecting samples and data from patients with and without known infection and testing for viral disease together with assessments of inflammatation and immune status. Of potential concern is the use of hydroxychloroquine in patients with Gaucher disease, as the drug is trapped in lysosomal compartments and distrupts lysosomal function. [63] Therefore, patients with an already pre-existing or inborn lysosomal dysfunction may have an increased risk of adverse effects of the drug.

For this reason, we would generally try to avoid treatment with hydroxychloroquine, and strongly discourage the 'prophylactic' use of this drug.

The 2020 SARS-CoV-2 pandemic has introduced many unanticipated challenges related to the treatment and support of patients with rare disease. Like with GD, other inborn errors of metabolism likely have unique aspects that must be considered during these uncertain times.

Prospective plans for patient management and for collecting and communicating disease parameters real-time are essential for providing optimal care during the current pandemic and potentially in the future.

Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) -United States

Epidemiology of Covid-19 in a Long-Term Care Facility in King County

Gaucher disease: Progress and ongoing challenges

The Online Metabolic and Molecular Bases of Inherited Disease

Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy

Gaucher disease and comorbidities: B-cell malignancy and parkinsonism

The Spectrum of Neurological Manifestations Associated with Gaucher Disease. Diseases

The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease

Gaucher disease: complexity in a "simple" disorder

Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs

Antigen-mediated regulation in monoclonal gammopathies and myeloma

Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease

An unexpected player in Gaucher disease: The multiple roles of complement in disease development

Efferocytosis is impaired in Gaucher macrophages

Immunological cells and functions in Gaucher disease

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry

Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial

What we know so far: COVID-19 current clinical knowledge and research

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal

Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System

Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses

COVID-19: consider cytokine storm syndromes and immunosuppression

Clinical and immunological features of severe and moderate coronavirus disease 2019

Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages

Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease

The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes. medRxiv

Immunopathogenesis of coronavirus infections: implications for SARS

SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes

Aberrant pathogenic GM-CSF<sup>+</sup> T cells and inflammatory CD14<sup>+</sup>CD16<sup>+</sup> monocytes in severe pulmonary syndrome patients of a new coronavirus

Persistent immune alterations and comorbidities in splenectomized patients with Gaucher disease

Gaucher disease and dysgammaglobulinemia: a report of 61 patients, including 18 with GD type III

Gammopathy and B lymphocyte clonality in patients with Gaucher type I disease

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma

Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: A state-of-the art review

Massive splenomegaly and Epstein-Barr virusassociated infectious mononucleosis in a patient with Gaucher disease

Case Report Serious pulmonary infection in a splenectomized patient with adult type 1 Gaucher disease

Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease

Life expectancy in Gaucher disease type 1

Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States

Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data. Syst Rev

Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1

Glucosylsphingosine is a key biomarker of Gaucher disease

Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1

Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between

Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Clinical Characteristics of Coronavirus Disease 2019 in China

Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers

Type 1 Gaucher disease (CYP2D6-eliglustat)

Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States

CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings

Neuronopathic forms of Gaucher's disease

Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype

Unusual expression of Gaucher's disease: cardiovascular calcifications in three sibs homozygous for the D409H mutation

Coronavirus infections and immune responses

Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 italian Gaucher type I patients

Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply

A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1

Chloroquine inhibits autophagic flux by decreasing autophagosomelysosome fusion